Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2, 2007. The report details an application made to the UK Listing Authority and the London Stock Exchange for the block listing and admission to the Official List of new ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate action report regarding share issuance rather than a financial performance statement.
Material Changes
The material change reported is the authorization of new share issuances to support executive share option plans. Specifically, the company applied for block listings totaling 2,100,000 Ordinary shares of 25p each, plus an additional listing application for 64,491 Ordinary shares of 25p each. These shares rank equally with existing issued shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The unusual item noted is the specific breakdown of the share issuance:
- 100,000 shares under the SmithKline Beecham 1989 Executive Share Option Plan - Unapproved.
- 2,000,000 shares under the GlaxoSmithKline Share Option Plan.
- 64,491 shares issued under the SmithKline Beecham 1989 Executive Share Option Plan - Unapproved and the Glaxo Group Limited Share Option Scheme.
Investor Verification Checklist
- Verify the final admission of the 2,164,491 total new shares to the Official List.
- Confirm the impact of this dilution on existing shareholders' equity.
- Review the specific terms of the SmithKline Beecham 1989 and GlaxoSmithKline Share Option Plans referenced.